1 / 22

Hepatitis C: Overview and Epidemiology

Hepatitis C: Overview and Epidemiology. Heidar Sharafi, PhDc. Baqiyatallah Research Center for Gastroenterology and Liver Disease (BRCGL). Hepatitis C Virus. Natural History of Hepatitis C. Exposure. Acute or Early Phase. Chronic HCV 65-80%. Resolved 20-35%. Cirrhosis 5-25%.

tasha
Télécharger la présentation

Hepatitis C: Overview and Epidemiology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis C: Overview and Epidemiology Heidar Sharafi,PhDc Baqiyatallah Research Center for Gastroenterology and Liver Disease (BRCGL)

  2. Hepatitis C Virus

  3. Natural History of Hepatitis C Exposure Acute or Early Phase Chronic HCV65-80% Resolved20-35% Cirrhosis5-25% Stable75-95% Stable 97-99%/yr HCC or Decompensation1-3%/yr Hajarizadeh et al. Nat Rev Gastroenterol Hepatol. 2013.

  4. Pattern of Acute HCV Infection with Progression to Chronic Infection anti-HCV Symptoms +/- HCV RNA Titer ALT Normal 6 1 2 3 4 0 1 2 3 4 5 Years Months Time after Exposure

  5. Pattern of Acute HCV Infection with Progression to Spontaneous Clearance anti-HCV Symptoms +/- HCV RNA Titer ALT Normal 6 1 2 3 4 0 1 2 3 4 5 Years Months Time after Exposure

  6. Mortality Rates Due to HIV, HCV, and HBV Infections in the US 7 6 5 4 3 2 1 0 HIV Rate per100,000 PY* HepatitisC HepatitisB Yr Ly KN, et al. Ann Intern Med. 2012

  7. Given the high coverage of HBV vaccination in infants and implementation of HBV vaccination programs among adolescent in Iran, HCV seems to emerge as the leading cause of viral hepatitis-related advanced liver disease and death in the near future.

  8. First study investigated prevalence of HCV in Iran was performed by Rezvan et al and found 0.3% of blood donors inTehran to be positive for HCV antibody. Rezvan et al. Vox Sang 1994

  9. The Main RiskFactors of HCV in Iranian Blood Donors 0.12% were HCVpositive No apparent risk factors could be demonstrated in 24.5%of the positive cases. Alavian et al. J Gastroenterol Hepatol. 2002

  10. HCV in Drug Users Drug users with an injection history, 45% (37–54%) Drug users without an injection history, 8% (4–13%)

  11. HCV in Inherited Disorders of Hemoglobin Its Seroepidemiology ranged from 2 to 32%. Pooled HCV infection rate was 18% Alavian et al.Iran Red Cres Med J. 2010

  12. After initiation of donors screening for HCV in 1996 and exclusion of high-risk groups from donation pool, the prevalence of HCV infection in thalassemia patients had decreased significantly in Iran. Alavian et al. Transfusion Today. 2003

  13. HCV in Inherited Bleeding Disorders The estimate of HCV infection among patients with inherited coagulation disorders was 48.07%in Iran.

  14. HCV in Hemodialysis Patients Alavian et al. J Public Health (Oxf). 2011.

  15. PrevalenceofpositiveHCVAbsinpatientsonhemodialysisdecreasedfrom14.4%in 1999 to 4.5% in 2006.

  16. In a study in three prisons in three central provinces of Iran (Isfahan, Lorestan, Chaharmahal va Bakhtiari) in 2003 in male prisoners who were arrested because of their addiction • 3.5% were HBs Ag positive and 35.8% were HCV antibody. • According the age, the infection with HBV and HCV were more common in younger than 30 yrs. old. • Isfahan , Lorestan and Chaharmahal va Bakhtiari: Addicted • respectively, 28.5%, 50% , 53% HCVinfected • IUDs, Tattooing history, In jail more than 5 yearswereimportant arrested Javadi et al. Iran J Public Health. 2006

  17. HCV in General Population of Iran • Merat et al. found 0.5% HCV seropositivity in a population-based study in 2006. • Mirminachi et al. estimated seroprevalence of HCV as 0.6% among Iranian general population based on a systematic review. • With 0.5% prevalence, population of 82,000,000 and 70% viremia, there will be 287000 infected cases needs treatment. • Hajarizadeh et al. estimated the total number of infected cases with viremia to be 187000.

  18. Distribution of HCV Genotypes in Iran Ghaderi-Zefrehi et al. Hepat mon. 2016.

  19. The projection of HCV disease burden by 2030, assuming the current diagnosis (6000) and treatment uptake (4500) and utilising interferon-based treatment Number of individuals living with HCV infection (Shaded area represents 95% confidence interval) Number of individuals with HCV-related decompensated cirrhosis and hepatocellular carcinoma Hajarizadeh et al. Hepat Mon. 2016.

  20. The projection of HCV disease burden by 2030, assuming the increasing diagnosis and treatment uptake and utilising interferon-free treatment • Stepwise Increase in diagnosis • 6,000 (2016 - 2017) • 12,000 (2018 - 2019) • 24,000 (2020 - 2030) • Stepwise treatment increase • 9,000 (2016 -2017) • 18,000 (2018 - 2030) Hajarizadeh et al. Hepat Mon. 2016.

  21. The projection of HCV disease burden by 2030, assuming the increasing diagnosis and treatment uptake and utilising interferon-free treatment • Stepwise Increase in diagnosis • 6,000 (2016 - 2017) • 12,000 (2018 - 2019) • 24,000 (2020 - 2030) • Stepwise treatment increase • 9,000 (2016 -2017) • 18,000 (2018 - 2030) Hajarizadeh et al. Hepat Mon. 2016.

  22. Special Thanks to • Prof. Seyed Moayed Alavian • Dr. Mohammad Saeid Rezaee-Zavareh • Dr. Behzad Hajarizadeh

More Related